Candidates

  • Inhibitors targeting DNA Damage Response (DDR)

    DNA Damage Response Inhibition is an anti-cancer platform which could revolutionize the treatment of cancer. It works by exploiting DNA Damage Response defects which are specific to cancer cells and kills them whilst sparing normal cells.

    MORE
  • PARP Iinhibitors

    IMPACT has discovered two series of novel PARP inhibitors with more than 60 novel compounds that are many folds more potent than AZD2281 (Olaparib) in multiple in vitro assays, and selected IMP4297 as a clinical candidate for development based on excellent pharmacological and safety profiles.

    MORE
  • Hedgehog Pathway Inhibitors

    IMPACT has discovered three series of novel Hedgehog pathway inhibitors and has identified more than 10 compounds that are 10-100 folds more potent than the approved Hedgehog inhibitor GDC-0449 (Vismodegib) in multiple in vitro assays.

    MORE
  • Microtubule Inhibitor

    IMPACT has discovered two series of novel small molecular microtubule inhibitors, and selected IMP3138 as a clinical candidate for further development.

    MORE

About Impact

Funded by venture capital and based in China, IMPACT Therapeutics, Inc. (IMPACT) is dedicated to the discovery, development and commercialization of novel and “best-in-class” therapeutics to treat cancer and other life-threatening diseases.

MORE

Join us

IMPACT regards employees as the most valuable asset of the company, willing to absorb all outstanding and potential talents, and provides a broad career development space for each employee.

MORE